Trump’s 200% generic tariff threat would imperil Americans: Indian pharma
U.S. President Donald Trump announced that starting August 1, 2026, generic drugs imported into the U.S. will face a 100% tariff after a two-year grace period, escalating to 200% thereafter. Indian pharmaceutical companies warned that such tariffs would jeopardize access to affordable medications for Americans. The proposed tariffs could significantly impact the U.S. healthcare system and the global pharmaceutical supply chain.